EUCTR2010-019360-36-GB
Active, not recruiting
Not Applicable
Pilot study of treatment of depression in refractory asthma - Treatment of depression in refractory asthma
ConditionsRefractory Asthma Depression
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Refractory Asthma Depression
- Sponsor
- Belfast Health and Social Care Trust
- Status
- Active, not recruiting
- Last Updated
- 13 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Refractory asthma as defined by persisting symptoms due to asthma (Asthma control score \=3\), despite detailed assessment and management of alternative diagnoses, non\-adherence, co\-morbidites etc. Minimal maintenance therapy of high dose inhaled steroids (\=800mcg BDP or equivalent), long acting beta\-agonist and/or other maintenance therapies. The requirement for maintenance steroids for \=50% of the year or at least 3 courses of systemic steroids in preceding 12 months. 2\. Hosptial Anxiety Depression Scale of \=11 and Hamiliton Rating scale \=17\.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 0
- •F.1\.3 Elderly (\>\=65 years) no
- •F.1\.3\.1 Number of subjects for this age range 0
Exclusion Criteria
- •1\. Poor medication adherence 2\. Significant co\-morbidity due to condition other than asthma 3\. Anti\-depressant medication in previous 3 months 4\. Pregnancy 5\. Patients requiring NSAID’s, aspirin or warfarin 6\. Patients with reduced hepatic function 7\. Patients with any history of cardiac disease 8\. Patients with congenital long QT syndrome or known pre\-existing QT interval prolongation taking other medicines known to prolong QT interval. 9\. Patients with pre\-existing risk factors for QT interval prolongation, including patients with significant bradycardia, recent acute myocardial infarction or decompensated heart failure. 10\. Patients with electrolyte disturbances (eg, hypokalaemia and hypomagnesaemia). 11\. Patients taking concomitant medications known to increase plasma levels of citalopram such as: \- some antiretroviral medications \- omeprazole \- cimetidine
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 2
Pilot study for the rapid alleviation of depression in depressed alcohol dependent persons using ketamineACTRN12610000390088niversity of Otago24
Terminated
Phase 4
Sequential Tranylcypromine (TC), TC + Dextroamphetamine and TC + Triiodothyronine for Refractory DepressionMajor DepressionNCT00296686New York State Psychiatric Institute31
Not yet recruiting
Not Applicable
Intervention for the Treatment of Depression in Virtual Reality (FlowVR)F32F32.1F32.2F32.8F32.9F33F33.1F33.2F33.8F33.9Depressive episodeModerate depressive episodeSevere depressive episode without psychotic symptomsOther depressive episodesDepressive episode, unspecifiedRecurrent depressive disorderRecurrent depressive disorder, current episode moderateRecurrent depressive disorder, current episode severe without psychotic symptomsOther recurrent depressive disordersRecurrent depressive disorder, unspecifiedDRKS00034078Asklepois Klinikum Harburg Zentrum für seelische Gesundheit Klinik für Psychiatrie, Psychotherapie und Psychosomatik66
Completed
Not Applicable
Clinical study of treatment for depressed lesions using cultured adipose derived stem cells.depressed lesionJPRN-UMIN000020530niversity of the Ryukyus Hospital11
Completed
Not Applicable
The investigation of treatment for major depression compared monotherapy of mirtazapine, sertraline or duloxetine with combination therapy of mirtazapine and sertraline, or mirtazapine and duloxetineMajor depressionJPRN-UMIN000004567Kenichi Osada500